Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Elihu Estey

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Phase II as Topic Clinical Trials

Phenomena

Recurrence

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
49
Kantarjian, Hagop
28
Keating, Michael
22
O'Brien, Susan
22
Giles, Francis
21
Freireich, Emil
17
Beran, Miloslav
17
Pierce, Sherry
16
Thall, Peter
14
Andreeff, Michael
13
Talpaz, Moshe
13
Albitar, Maher
12
Cortes, Jorge
12
Estrov, Zeev
12
Kurzrock, Razelle
9
Kornblau, Steven

Sign-in to see all Coauthors

Publications

TOP 3
Schimmer Aaron D; Estey Elihu H; Borthakur Gautam; Carter Bing Z; Schiller Gary J; Tallman Martin S; Altman Jessica K; Karp Judith E; Kassis Jeannine; Hedley David W; Brandwein Joseph; Xu Wei; Mak Duncan H; LaCasse Eric; Jacob Christine; Morris Stephen J; Jolivet Jacques; Andreeff Michael
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
Heinrichs S; Kulkarni R V; Bueso-Ramos C E; Levine R L; Loh M L; Li C; Neuberg D; Kornblau S M; Issa J-P; Gilliland D G; Garcia-Manero G; Kantarjian H M; Estey E H; Look A T
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.
Albitar Maher; Potts Steven J; Giles Francis J; O'Brien Susan; Jilani Iman; Donahue Amber C; Estey Elihu H; Kantarjian Hagop
Proteomics-based prediction of clinical response in acute myeloid leukemia.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Elihu Estey (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Schimmer Aaron D; Estey Elihu H; Borthakur Gautam; Carter Bing Z; Schiller Gary J; Tallman Martin S; Altman Jessica K; Karp Judith E; Kassis Jeannine; Hedley David W; Brandwein Joseph; Xu Wei; Mak Duncan H; LaCasse Eric; Jacob Christine; Morris Stephen J; Jolivet Jacques; Andreeff Michael
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4741-6.
2009: Heinrichs S; Kulkarni R V; Bueso-Ramos C E; Levine R L; Loh M L; Li C; Neuberg D; Kornblau S M; Issa J-P; Gilliland D G; Garcia-Manero G; Kantarjian H M; Estey E H; Look A T
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(9):1605-13.
2009: Albitar Maher; Potts Steven J; Giles Francis J; O'Brien Susan; Jilani Iman; Donahue Amber C; Estey Elihu H; Kantarjian Hagop
Proteomics-based prediction of clinical response in acute myeloid leukemia.
Experimental hematology 2009;37(7):784-90.
2009: Estey Elihu H
Incorporating novel treatment strategies into conventional therapy.
Clinical advances in hematology & oncology : H&O 2009;7(6):4-7.
2009: Zeng Zhihong; Shi Yue Xi; Samudio Ismael J; Wang Rui-Yu; Ling Xiaoyang; Frolova Olga; Levis Mark; Rubin Joshua B; Negrin Robert R; Estey Elihu H; Konoplev Sergej; Andreeff Michael; Konopleva Marina
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
Blood 2009;113(24):6215-24.
2009: Walter Roland B; Estey Elihu H
The power of comparative studies.
Leukemia research 2009;33(5):610-2.
2009: Sanz Miguel A; Grimwade David; Tallman Martin S; Lowenberg Bob; Fenaux Pierre; Estey Elihu H; Naoe Tomoki; Lengfelder Eva; Büchner Thomas; Döhner Hartmut; Burnett Alan K; Lo-Coco Francesco
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Blood 2009;113(9):1875-91.
2009: Calado Rodrigo T; Regal Joshua A; Hills Mark; Yewdell William T; Dalmazzo Leandro F; Zago Marco A; Lansdorp Peter M; Hogge Donna; Chanock Stephen J; Estey Elihu H; Falcão Roberto P; Young Neal S
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(4):1187-92.
2009: Estey Elihu H
Treatment of acute myeloid leukemia.
Haematologica 2009;94(1):10-6.
2008: Borthakur Gautam; Kantarjian Hagop; Wang Xuemei; Plunkett William K; Gandhi Varsha V; Faderl Stefan; Garcia-Manero Guillermo; Ravandi Farhad; Pierce Sherry; Estey Elihu H
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Cancer 2008;113(11):3181-5.
2008: Thall Peter F; Nguyen Hoang Q; Estey Elihu H
Patient-specific dose finding based on bivariate outcomes and covariates.
Biometrics 2008;64(4):1126-36.
2008: Wathen J Kyle; Thall Peter F; Cook John D; Estey Elihu H
Accounting for patient heterogeneity in phase II clinical trials.
Statistics in medicine 2008;27(15):2802-15.
2008: Estey Elihu H
Older adults: should the paradigm shift from standard therapy?
Best practice & research. Clinical haematology 2008;21(1):61-6.
2008: Tsimberidou Apostolia-Maria; Kantarjian Hagop M; Wen Sijin; O'Brien Susan; Cortes Jorge; Wierda William G; Koller Charles; Pierce Sherry; Brandt Mark; Freireich Emil J; Keating Michael J; Estey Elihu H
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):721-30.
2008: Kurzrock Razelle; Kantarjian Hagop M; Blascovich Michelle A; Bucher Cindy; Verstovsek Srdan; Wright John J; Pilat Susan R; Cortes Jorge E; Estey Elihu H; Giles Francis J; Beran Miloslav; Sebti Said M
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):509-14.
2008: Strom Sara S; Vélez-Bravo Vivianne; Estey Elihu H
Epidemiology of myelodysplastic syndromes.
Seminars in hematology 2008;45(1):8-13.
2007: Soriano Andres O; Yang Hui; Faderl Stefan; Estrov Zeev; Giles Francis; Ravandi Farhad; Cortes Jorge; Wierda William G; Ouzounian Souzanne; Quezada Andres; Pierce Sherry; Estey Elihu H; Issa Jean-Pierre J; Kantarjian Hagop M; Garcia-Manero Guillermo
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Blood 2007;110(7):2302-8.
2007: Sun Xiaoping; Zhang Wei; Ramdas Latha; Stivers David N; Jones Daniel M; Kantarjian Hagop M; Estey Elihu H; Vadhan-Raj Saroj; Medeiros L Jeffrey; Bueso-Ramos Carlos E
Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2007;20(8):811-20.
2007: Aribi Ahmed; Kantarjian Hagop M; Estey Elihu H; Koller Charles A; Thomas Deborah A; Kornblau Steven M; Faderl Stefan H; Laddie Nakia M; Garcia-Manero Guillermo; Cortes Jorge E
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Cancer 2007;109(7):1355-9.
2007: Estey Elihu H
Advances in the management of AML in the elderly.
Clinical advances in hematology & oncology : H&O 2007;5(3):185-7.
2006: Appelbaum Frederick R; Kopecky Kenneth J; Tallman Martin S; Slovak Marilyn L; Gundacker Holly M; Kim Haesook T; Dewald Gordon W; Kantarjian Hagop M; Pierce Sherry R; Estey Elihu H
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
British journal of haematology 2006;135(2):165-73.
2006: Kornblau Steven M; Womble Matthew; Qiu Yi Hua; Jackson C Ellen; Chen Wenjing; Konopleva Marina; Estey Elihu H; Andreeff Michael
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.
Blood 2006;108(7):2358-65.
2006: Kern Wolfgang; Estey Elihu H
High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.
Cancer 2006;107(1):116-24.
2006: Estey Elihu H
General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia.
Seminars in hematology 2006;43(2):89-95.
2006: Thall Peter F; Estey Elihu H; Markman Maurie
Some ethical issues in phase II trials in acute leukemia.
Clinical advances in hematology & oncology : H&O 2006;4(2):95.
2006: Mattiuzzi Gloria N; Alvarado Gladys; Giles Francis J; Ostrosky-Zeichner Luis; Cortes Jorge; O'brien Susan; Verstovsek Srdan; Faderl Stefan; Zhou Xian; Raad Issam I; Bekele B Nebiyou; Leitz G J; Lopez-Roman Ivonne; Estey Elihu H
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
Antimicrobial agents and chemotherapy 2006;50(1):143-7.
2006: Huang Xuelin; Biswas Swati; Estey Elihu H; Berry Donald A
Building and validating a prognostic index for biomarker studies.
Cancer biomarkers : section A of Disease markers 2006;2(3-4):97-101.
2006: Thall Peter F; Cook John D; Estey Elihu H
Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
Journal of biopharmaceutical statistics 2006;16(5):623-38.
2005: Thall Peter F; Estey Elihu H
Some ethical issues in phase II trials in acute leukemia.
Clinical advances in hematology & oncology : H&O 2005;3(12):943-8.
2005: Strom S S; Gu Y; Gruschkus S K; Pierce S A; Estey E H
Risk factors of myelodysplastic syndromes: a case-control study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(11):1912-8.
2005: Larson Richard A; Sievers Eric L; Stadtmauer Edward A; Löwenberg Bob; Estey Elihu H; Dombret Hervé; Theobald Matthias; Voliotis Dimitris; Bennett John M; Richie Maria; Leopold Lance H; Berger Mark S; Sherman Matthew L; Loken Michael R; van Dongen Jacques J M; Bernstein Irwin D; Appelbaum Frederick R
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Cancer 2005;104(7):1442-52.
2005: Amin H M; Yang Y; Shen Y; Estey E H; Giles F J; Pierce S A; Kantarjian H M; O'Brien S M; Jilani I; Albitar M
Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(9):1567-72.
2005: Heinrichs Stefan; Berman Jason N; Ortiz Taylor M; Kornblau Steven M; Neuberg Donna S; Estey Elihu H; Look A Thomas
CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome.
British journal of haematology 2005;130(1):83-6.
2005: Hosing C; Saliba R M; Shahjahan M; Estey E H; Couriel D; Giralt S; Andersson B; Champlin R E; De Lima M
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.
Bone marrow transplantation 2005;36(2):157-62.
2005: Loh Mignon L; Martinelli Simone; Cordeddu Viviana; Reynolds Melissa G; Vattikuti Shashaank; Lee Connie M; Wulfert Michael; Germing Ulrich; Haas Peter; Niemeyer Charlotte; Beran Miloslav E; Strom Sara; Lübbert Michael; Sorcini Mariella; Estey Elihu H; Gattermann Norbert; Tartaglia Marco
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia research 2005;29(4):459-62.
2005: Estey Elihu H
"3+7" therapy for the treatment of acute myeloid leukemia. CON.
Clinical advances in hematology & oncology : H&O 2005;3(2):129-132, 141.
2004: Estey Elihu H
Modulation of angiogenesis in patients with myelodysplastic syndrome.
Best practice & research. Clinical haematology 2004;17(4):623-39.
2004: Hu Qinglong; Dey Amanda L; Yang Ying; Shen Yu; Jilani Iman B; Estey Elihu H; Kantarjian Hagop M; Giles Francis J; Albitar Maher
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Cancer 2004;100(9):1884-91.
2004: Kurzrock Razelle; Albitar Maher; Cortes Jorge E; Estey Elihu H; Faderl Stefan H; Garcia-Manero Guillermo; Thomas Deborah A; Giles Francis J; Ryback Mary Ellen; Thibault Alain; De Porre P; Kantarjian Hagop M
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1287-92.
2004: Lin Pei; Hao Suyang; Medeiros L Jeffrey; Estey Elihu H; Pierce Sherry A; Wang Xuemei; Glassman Armand B; Bueso-Ramos Carlos; Huh Yang O
Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis.
American journal of clinical pathology 2004;121(3):402-7.
2004: Tabe Yoko; Konopleva Marina; Munsell Mark F; Marini Frank C; Zompetta Claudia; McQueen Teresa; Tsao Twee; Zhao Shourong; Pierce Sherry; Igari Jun; Estey Elihu H; Andreeff Michael
PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival.
Blood 2004;103(5):1815-22.
2003: Cheson Bruce D; Bennett John M; Kopecky Kenneth J; Büchner Thomas; Willman Cheryl L; Estey Elihu H; Schiffer Charles A; Doehner Hartmut; Tallman Martin S; Lister T Andrew; Lo-Coco Francesco; Willemze Roel; Biondi Andrea; Hiddemann Wolfgang; Larson Richard A; Löwenberg Bob; Sanz Miguel A; Head David R; Ohno Ryuzo; Bloomfield Clara D;
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4642-9.
2003: Yazji S; Giles F J; Tsimberidou A-M; Estey E H; Kantarjian H M; O'Brien S A; Kurzrock R
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(11):2101-6.
2003: Estey Elihu H; Thall Peter F; Wang Xuemei; Verstovsek Srdan; Cortes Jorge; Kantarjian Hagop M
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
Blood 2003;102(9):3097-9.
2003: Hock Barry D; McKenzie Judith L; Patton William Nigel; Haring Lisa F; Yang Ying; Shen Yu; Estey Elihu H; Albitar Maher
The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
Cancer 2003;98(8):1681-8.
2003: Wong Raymond; Giralt Sergio A; Martin Thomas; Couriel Daniel R; Anagnostopoulos Athanasios; Hosing Chitra; Andersson Borje S; Cano Pedro; Shahjahan Munir; Ippoliti Cindy; Estey Elihu H; McMannis John; Gajewski James L; Champlin Richard E; de Lima Marcos
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.
Blood 2003;102(8):3052-9.
2003: Estey Elihu H
Treatment options for relapsed acute promyelocytic leukaemia.
Best practice & research. Clinical haematology 2003;16(3):521-34.
2003: Giles Francis J; Cortes Jorge E; Halliburton Terri A; Mallard Susie J; Estey Elihu H; Waddelow Tracey A; Lim JoAnn T
Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.
The Annals of pharmacotherapy 2003;37(9):1182-5.
2003: Estey Elihu H
Adaptive randomization in a treatment study of patients with adverse karyotype acute myeloid leukemia.
Current oncology reports 2003;5(5):390.
2003: Estey Elihu H
Early blast clearance by remission induction as a prognostic factor in acute myeloid leukemia.
Current oncology reports 2003;5(5):389.
2003: Gatto Simona; Ball Greg; Onida Francesco; Kantarjian Hagop M; Estey Elihu H; Beran Miloslav
Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS).
Blood 2003;102(5):1622-5.
2003: Amin Hesham M; Jilani Iman; Estey Elihu H; Keating Michael J; Dey Amanda L; Manshouri Taghi; Kantarjian Hagop M; Estrov Zeev; Cortes Jorge E; Thomas Deborah A; Giles Francis J; Albitar Maher
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.
Blood 2003;102(5):1866-8.
2003: Konopleva Marina; Cheng Su-Chun; Cortes Jorge E; Hayes Kimberly J; Pierce Sherry A; Andreeff Michael; Giles Francis J; O'Brien Susan; Kantarjian Hagop M; Estey Elihu H
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
Haematologica 2003;88(7):733-6.
2003: Estey Elihu H; Thall Peter F
New designs for phase 2 clinical trials.
Blood 2003;102(2):442-8.
2003: Giles Francis J; Kantarjian Hagop M; Cortes Jorge E; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stefan; Thomas Deborah A; Ferrajoli Alessandra; O'Brien Susan; Wathen Jay K; Xiao Lian-Chun; Berry Donald A; Estey Elihu H
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1722-7.
2003: Leopold Lance H; Berger Mark S; Cheng Su-Chun; Cortes-Franco Jorge E; Giles Francis J; Estey Elihu H
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Clinical advances in hematology & oncology : H&O 2003;1(4):220-5.
2003: Giles Francis J; Faderl Stefan; Thomas Deborah A; Cortes Jorge E; Garcia-Manero Guillermo; Douer Dan; Levine Alexandra M; Koller Charles A; Jeha Sima S; O'Brien Susan M; Estey Elihu H; Kantarjian Hagop M
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1050-6.
2003: Estey Elihu H
Current challenges in therapy of myelodysplastic syndromes.
Current opinion in hematology 2003;10(1):60-7.
2002: Aguayo Alvaro; Kantarjian Hagop M; Estey Elihu H; Giles Francis J; Verstovsek Srdan; Manshouri Taghi; Gidel Christy; O'Brien Susan; Keating Michael J; Albitar Maher
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Cancer 2002;95(9):1923-30.
2002: Meyers Christina A; Seabrooke Lee F; Albitar Maher; Estey Elihu H
Association of cancer-related symptoms with physiological parameters.
Journal of pain and symptom management 2002;24(4):359-61.
2002: Albitar Maher; Manshouri Taghi; Shen Yu; Liu Diane; Beran Miloslav; Kantarjian Hagop M; Rogers Anna; Jilani Iman; Lin Chung Wu; Pierce Sherry; Freireich Emil J; Estey Elihu H
Myelodysplastic syndrome is not merely "preleukemia".
Blood 2002;100(3):791-8.
2002: Estey Elihu H; Thall Peter F; Giles Francis J; Wang Xue-Mei; Cortes Jorge E; Beran Miloslav; Pierce Sherry A; Thomas Deborah A; Kantarjian Hagop M
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Blood 2002;99(12):4343-9.
2002: Estey Elihu H; Giles Francis J; Beran Miloslav; O'Brien Susan; Pierce Sherry A; Faderl Stefan H; Cortes Jorge E; Kantarjian Hagop M
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
Blood 2002;99(11):4222-4.
2002: Estey Elihu H
Treatment of acute myelogenous leukemia.
Oncology (Williston Park, N.Y.) 2002;16(3):343-52, 355-6; discussion 357, 362, 365-6.
2002: Estey E H
New drugs for therapy of AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(3):306-9.
2002: Gandhi Varsha; Plunkett William; Du Min; Ayres Mary; Estey Elihu H
Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):665-73.
2002: Onida Francesco; Kantarjian Hagop M; Smith Terry L; Ball Greg; Keating Michael J; Estey Elihu H; Glassman Armand B; Albitar Maher; Kwari Monica I; Beran Miloslav
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.
Blood 2002;99(3):840-9.
2001: Estey E H; Thall P F; Cortes J E; Giles F J; O'Brien S; Pierce S A; Wang X; Kantarjian H M; Beran M
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Blood 2001;98(13):3575-83.
2001: Beran M; Shen Y; Kantarjian H; O'Brien S; Koller C A; Giles F J; Cortes J; Thomas D A; Faderl S; Despa S; Estey E H
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Cancer 2001;92(8):1999-2015.
2001: Estey E H
Therapeutic options for acute myelogenous leukemia.
Cancer 2001;92(5):1059-73.
2001: Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno N T; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson B S; Estey E H; Champlin R; Przepiorka D
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
American journal of hematology 2001;67(4):227-33.
2001: Giles F J; Kantarjian H M; Kornblau S M; Thomas D A; Garcia-Manero G; Waddelow T A; David C L; Phan A T; Colburn D E; Rashid A; Estey E H
Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Cancer 2001;92(2):406-13.
2001: Estey E H
Prognostic factors in acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(4):670-2.
2001: Estey E H
Growth factors in acute myeloid leukaemia.
Best practice & research. Clinical haematology 2001;14(1):175-87.
2000: Ibrahim S; Estey E H; Pierce S; Glassman A; Keating M; O'Brien S; Kantarjian H M; Albitar M
11q23 abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses.
American journal of clinical pathology 2000;114(5):793-7.
2000: Estey E H
How I treat older patients with AML.
Blood 2000;96(5):1670-3.
2000: Estey E H
Treatment of relapsed and refractory acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(3):476-9.
2000: Estey E H; Pierce S; Keating M J
Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities.
Haematologica 2000;85(3):246-9.
2000: Estey E H; Shen Y; Thall P F
Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB.
Blood 2000;95(1):72-7.
1999: Andreeff M; Jiang S; Zhang X; Konopleva M; Estrov Z; Snell V E; Xie Z; Okcu M F; Sanchez-Williams G; Dong J; Estey E H; Champlin R C; Kornblau S M; Reed J C; Zhao S
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(11):1881-92.
1999: Estrov Z; Manna S K; Harris D; Van Q; Estey E H; Kantarjian H M; Talpaz M; Aggarwal B B
Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells.
Blood 1999;94(8):2844-53.
1999: Estey E H; Giles F J; Kantarjian H; O'Brien S; Cortes J; Freireich E J; Lopez-Berestein G; Keating M
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.
Blood 1999;94(7):2230-5.
1999: Aboul-Nasr R; Estey E H; Kantarjian H M; Freireich E J; Andreeff M; Johnson B J; Albitar M
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens.
American journal of clinical pathology 1999;111(6):753-8.
1999: Weinkauff R; Estey E H; Starostik P; Hayes K; Huh Y O; Hirsch-Ginsberg C; Andreeff M; Keating M; Kantarjian H M; Freireich E J; Albitar M
Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia.
American journal of clinical pathology 1999;111(6):733-40.
1999: Thall P F; Lee J J; Tseng C H; Estey E H
Accrual strategies for phase I trials with delayed patient outcome.
Statistics in medicine 1999;18(10):1155-69.
1999: Estey E H; Thall P F; Pierce S; Cortes J; Beran M; Kantarjian H; Keating M J; Andreeff M; Freireich E
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Blood 1999;93(8):2478-84.
1999: Cortes J E; Kantarjian H M; O'Brien S; Giles F; Keating M J; Freireich E J; Estey E H
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cancer 1999;85(7):1506-13.
1999: Konopleva M; Mikhail A; Estrov Z; Zhao S; Harris D; Sanchez-Williams G; Kornblau S M; Dong J; Kliche K O; Jiang S; Snodgrass H R; Estey E H; Andreeff M
Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities.
Blood 1999;93(5):1668-76.
1999: Thall P F; Estey E H; Sung H G
A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials.
Investigational new drugs 1999;17(2):155-67.
1998: Estey E H
Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
Oncology (Williston Park, N.Y.) 1998;12(11A):81-6.
1998: Estrov Z; Thall P F; Talpaz M; Estey E H; Kantarjian H M; Andreeff M; Harris D; Van Q; Walterscheid M; Kornblau S M
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia.
Blood 1998;92(9):3090-7.
1998: Estey E H
New agents for the treatment of acute myelogenous leukemia: focus on topotecan and retinoids.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12 Suppl 1():S13-5.
1998: Ferrajoli A; Talpaz M; Kurzrock R; Harris D; Van Q; Estey E H; Estrov Z
Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation.
Leukemia & lymphoma 1998;30(3-4):279-92.
1998: Estey E H
Prognosis and therapy of secondary myelodysplastic syndromes.
Haematologica 1998;83(6):543-9.
1997: Peleg S; Qiu H; Reddy S; Harris D; Van Q; Estey E H; Talpaz M; Estrov Z
1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production.
The Journal of clinical investigation 1997;100(7):1716-24.
1996: Ghaddar H M; Pierce S; Kantarjian H M; Freireich E J; Keating M J; Estey E H
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
Leukemia & lymphoma 1996;22(1-2):71-6.
1996: Anderlini P; Ghaddar H M; Smith T L; Pierce S; Kantarjian H M; O'Brien S; Keating M J; Freireich E J; Estey E H
Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(6):964-9.
1996: Gandhi V; Estey E H; Keating M J; Plunkett W
Intracellular pharmacodynamics in leukemia therapy.
[Rinsho ketsueki] The Japanese journal of clinical hematology 1996;37(5):369-79.
1996: Kantarjian H M; Estey E H; Keating M A
New chemotherapeutic agents in acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10 Suppl 1():S4-6.
1996: Anderlini P; Luna M; Kantarjian H M; O'Brien S; Pierce S; Keating M J; Estey E H
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(4):600-8.
1996: Escudier S M; Kantarjian H M; Estey E H
Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.
Leukemia & lymphoma 1996;20(5-6):435-9.
1996: Thall P F; Simon R M; Estey E H
New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):296-303.
1995: Estrov Z; Black R A; Sleath P R; Harris D; Van Q; LaPushin R; Estey E H; Talpaz M
Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation.
Blood 1995;86(12):4594-602.
1995: Estrov Z; Talpaz M; Estey E H; Strassmann G
Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation.
Experimental hematology 1995;23(10):1080-7.
1995: Seymour J F; Estey E H; Keating M J; Kurzrock R
Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(5):929-32.
1995: Ghaddar H M; Pierce S; Reed P; Estey E H
Prognostic value of residual normal metaphases in acute myelogenous leukemia patients presenting with abnormal karyotype.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(5):779-82.
1995: Estey E H; Kantarjian H M; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Cytokines and molecular therapy 1995;1(1):21-8.
1995: Seymour J F; Estey E H
The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes.
Leukemia & lymphoma 1995;17(1-2):79-85.
1995: Marlton P; Claxton D F; Liu P; Estey E H; Beran M; LeBeau M; Testa J R; Collins F S; Rowley J D; Siciliano M J
Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis.
Blood 1995;85(3):772-9.
1995: Thall P F; Simon R M; Estey E H
Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.
Statistics in medicine 1995;14(4):357-79.
1995: Zhao L; Chang K S; Estey E H; Hayes K; Deisseroth A B; Liang J C
Detection of residual leukemic cells in patients with acute promyelocytic leukemia by the fluorescence in situ hybridization method: potential for predicting relapse.
Blood 1995;85(2):495-9.
1994: Ghaddar H M; Stass S A; Pierce S; Estey E H
Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(10):1649-53.
1994: Kantarjian H M; O'Brien S; Smith T; Estey E H; Beran M; Preti A; Pierce S; Keating M J
Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen.
British journal of haematology 1994;88(1):94-100.
1994: Ghaddar H M; Plunkett W; Kantarjian H M; Pierce S; Freireich E J; Keating M J; Estey E H
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(8):1269-74.
1994: Seymour J F; Kurzrock R; Freireich E J; Estey E H
2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia.
Blood 1994;83(10):2906-11.
1994: Seymour J F; Pierce S A; Kantarjian H M; Keating M J; Estey E H
Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(5):823-6.
1994: Maruyama F; Stass S A; Estey E H; Cork A; Hirano M; Ino T; Freireich E J; Yang P; Chang K S
Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(1):40-5.
1993: Estey E H; Kantarjian H; Keating M
Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Seminars in oncology 1993;20(6 Suppl 8):1-5.
1993: Seymour J F; Estey E H
The prognostic significance of auer rods in myelodysplasia.
British journal of haematology 1993;85(1):67-76.
1993: Thall P F; Estey E H
A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation.
Statistics in medicine 1993;12(13):1197-211.
1993: Jaiyesimi I A; Kantarjian H M; Estey E H
Advances in therapy for hairy cell leukemia. A review.
Cancer 1993;72(1):5-16.
1993: Reading C L; Estey E H; Huh Y O; Claxton D F; Sanchez G; Terstappen L W; O'Brien M C; Baron S; Deisseroth A B
Expression of unusual immunophenotype combinations in acute myelogenous leukemia.
Blood 1993;81(11):3083-90.
1993: Chang K S; Fan Y H; Stass S A; Estey E H; Wang G; Trujillo J M; Erickson P; Drabkin H
Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia.
Oncogene 1993;8(4):983-8.
1993: Estey E H; Plunkett W; Kantarjian H; Rios M B; Keating M J
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
Leukemia & lymphoma 1993;10 Suppl():115-21.
1993: Estey E H
Prognosis and therapy of myelodysplastic syndromes.
Cancer treatment and research 1993;64():233-67.
1992: Estrov Z; Park C H; Reading C L; Estey E H; Talpaz M; Kurzrock R; Deisseroth A B; Gutterman J U
The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors.
Experimental hematology 1992;20(7):886-90.
1992: Freireich E J; Cork A; Stass S A; McCredie K B; Keating M J; Estey E H; Kantarjian H M; Trujillo J M
Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(6):500-6.
1992: Estrov Z; Estey E H; Andreeff M; Talpaz M; Kurzrock R; Reading C L; Deisseroth A B; Gutterman J U
Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
Experimental hematology 1992;20(5):558-64.
1992: Kantarjian H M; Keating M J; Estey E H; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):772-8.
1992: Kantarjian H M; Estey E H; O'Brien S; Anaissie E; Beran M; Rios M B; Keating M J; Gutterman J
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia.
Blood 1992;79(4):876-81.
1992: Estey E H; Kurzrock R; Kantarjian H M; O'Brien S M; McCredie K B; Beran M; Koller C; Keating M J; Hirsch-Ginsberg C; Huh Y O
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).
Blood 1992;79(4):882-7.
1991: Kantarjian H M; Talpaz M; Keating M J; Estey E H; O'Brien S; Beran M; McCredie K B; Gutterman J; Freireich E J
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 1991;68(6):1201-7.
1991: Kurzrock R; Talpaz M; Gomez J A; Estey E H; O'Brien S; Hirsch-Ginsberg C; Koller C; Freireich E J; Gutterman J U
Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients.
British journal of haematology 1991;78(3):352-8.
1991: Estey E H; Kurzrock R; Talpaz M; McCredie K B; O'Brien S; Kantarjian H M; Keating M J; Deisseroth A B; Gutterman J U
Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
British journal of haematology 1991;77(3):291-5.
1990: Kantarjian H M; Walters R S; Keating M J; Smith T L; O'Brien S; Estey E H; Huh Y O; Spinolo J; Dicke K; Barlogie B
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(6):994-1004.
1990: Estey E H; Dixon D; Kantarjian H M; Keating M J; McCredie K; Bodey G P; Kurzrock R; Talpaz M; Freireich E J; Deisseroth A B
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor.
Blood 1990;75(9):1766-9.
1990: Estey E H; Keating M J; McCredie K B; Freireich E J; Plunkett W
Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(2):95-9.
1990: Kantarjian H M; Walters R L; Keating M J; Estey E H; O'Brien S; Schachner J; McCredie K B; Freireich E J
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
Cancer 1990;65(1):5-8.
1990: Estey E H; Kantarjian H M; Beran M; McCredie K B; Keating M J; Deisseroth A; Gutterman J U
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.
Haematology and blood transfusion 1990;33():732-6.
1989: Cason J D; Trujillo J M; Estey E H; Huh Y O; Freireich E J; Stass S A
Peripheral acute leukemia: high peripheral but low-marrow blast count.
Blood 1989;74(5):1758-61.
1987: Estey E H; Keating M J; McCredie K B; Freireich E J
Continuous-infusion amsacrine in patients with refractory acute myelogenous leukemia.
Cancer treatment reports 1987;71(11):1113-4.
1987: Estey E H; Keating M J; Dixon D O; Trujillo J M; McCredie K B; Freireich E J
Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
Hematologic pathology 1987;1(4):203-8.

Sign-in to see more